Key result
The ED50 and ED95 values of remimazolam besylate for procedural sedation during ERCP were 0.196 mg/kg and 0.239 mg/kg, respectively.
Why the study?
The study aimed to determine the half-effective dose (ED 50) and 95% effective dose (ED 95) of remimazolam besylate for procedural sedation during endoscopic retrograde cholangiopancreatography.
What are the effective doses (ED50 and ED95) of remimazolam besylate for procedural sedation during ERCP?
What are the effective doses (ED50 and ED95) of remimazolam besylate for procedural sedation during ERCP?
The ED50 and ED95 of remimazolam besylate for procedural sedation during ERCP are 0.196 and 0.239 mg/kg, respectively, demonstrating efficacy and safety.
Authors
No takes yet. Share an insight, caveat, or question.
May guide initial remimazolam dosing in ERCP; leaves open confirmation of safety in larger trials.
Tan et al. (2022) studied Endoscopic retrograde cholangiopancreatography (ERCP) (n=60). Remimazolam besylate was evaluated on Half-effective dose (ED50) and 95% effective dose (ED95). The ED50 and ED95 values of remimazolam besylate for procedural sedation during ERCP were 0.196 mg/kg and 0.239 mg/kg, respectively.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: